Baumer S.A

What it is

Baumer makes and sells hospital and health-industry equipment through four operating arms: Orthopedics (bone implants and surgical instruments), Hospital (operating-room and ICU gear), Genius (biomaterials), and Castanho (laundry equipment for hospitals and hotels).

Its product list spans orthopedic prostheses, spine and trauma implants, sterilisation systems for surgical centres, and life-science equipment for pharmaceutical and research labs. It also runs the Baumer Academy, an online training platform for health professionals in its product areas.

Who owns it

The company traces back to 1952, when Manoel Amaral Baumer — then just 22 years old — pivoted his small auto-parts workshop to make orthopaedic implants so that Brazilian surgeons could treat his wife after a car accident. Baumer went public in 1970 as Baumer Equipamento Médico Hospitalar S.A.; in 1988 the family consolidated control under a holding company, Baumer S.A.

The Baumer family remains firmly in charge: insiders hold 89.2% of the shares (EODHD), leaving a free float of only about 11% — which explains why trading volumes are thin. The stock trades on B3 as ordinary shares (BALM3) and preferred shares (BALM4).

Who runs it

Ruy Salvari Baumer serves as both Chairman of the Board and Chief Executive — a combined role that places a family member at the top of every decision. He also represents Baumer externally in Brazil’s industrial and healthcare associations.

No separate CFO is disclosed in publicly available filings; the dual role of Ruy Salvari Baumer as board chair and CEO is confirmed by CVM-sourced corporate data.

The money, in plain words

Sales have climbed steadily: BRL 170m (~US$33m) in 2023, BRL 194m (~US$37.5m) in 2024, and BRL 214m (~US$41m) in FY2025 — that is a 26% cumulative rise in two years (our calculation). Revenue grew 14.4% in 2024 and a further 9.9% in 2025 (our calculation), well above Brazil’s general inflation rate in both years.

The business keeps about 9 cents of profit from every real of sales — a net profit margin of 9.1%, solid for a mid-sized medical-device maker. For every real shareholders have invested, the company earns back roughly 13.5 cents a year — a return on equity of 13.5%, respectable though not exceptional.

The balance sheet is nearly clean: the company carries BRL 21.5m (~US$4.2m) in financial debt against BRL 16.1m (~US$3.1m) in cash, a net debt position of just BRL 5.4m (~US$1.0m) — barely worth calling leverage (our calculation). Owners’ equity stands at BRL 153m (~US$29.6m), giving it a solid financial cushion relative to its size.

The shares trade at 13.8 times earnings (price-to-earnings of 13.8×), a modest valuation for a company growing in double digits. The most recent dividend payment on BALM3 was BRL 3.07 (US$0.59)per share in December 2025 — a notable special distribution in a year of stronger profits, even though the EODHD data classifies the ordinary yield as zero because payments are irregular rather than recurring.

What it is doing now

Between 2020 and 2024, Baumer continued to expand its product and services portfolio, keeping pace with technological advances in its sector. In Brazil it operates alongside its affiliate Comércio e Importação Erecta in orthopedics and hospital equipment, and also through A.M.

Internacional, an import partner based in Chile, for regional reach.

The company paid out unusually large dividends in late 2025 — BRL 0.93 (US$0.18)per share in October and BRL 3.07 (US$0.59)in December — suggesting management felt the balance sheet had room to return cash after a period of strong operating cash generation. No acquisitions or major capital investments have been announced in available public sources to date.

What to watch

• Thin float, thin liquidity. With 89% of shares locked in family hands, the public market is small; any large buyer or seller moves the price sharply.
• Margin consistency. Net profit swung from BRL 8.9m (US$2 mn) in 2023 to BRL 31.6m (US$6 mn) in 2024 and back to BRL 18.1m (US$4 mn) in FY2025, suggesting lumpy costs or non-recurring items — watch for the underlying trend, not any single year’s number.
• Succession and governance. A single family member holding both the board chair and CEO role concentrates power; any leadership change would matter a great deal for a company this size.
• Brazil’s public-health budget. A significant share of Baumer’s customers are public hospitals — government procurement cycles and fiscal policy directly affect its order book.

This is news, not investment advice.